SuperworthANI Pharmaceuticals profit margin ANIP
Gross, operating and net profit as a share of revenue over the last twelve months, from 2013.
- Net margin, 12 months
- 11.1%
- Operating margin, 12 months
- 15.4%
- Net margin on a year earlier
- +12.4 pts
- Peer median
- 13.2%
Over the twelve months to Jun 30, 2026, ANI Pharmaceuticals kept 11.1% of its revenue as net profit, with an operating margin of 15.4% and a gross margin of 60.4%.
Five years earlier its net margin was −8.1%.
The median for 10 large drugmakers of a similar size is 13.2%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 8.9% | 12.6% | 61.4% |
| FY2024 | −3.0% | 0.1% | 59.3% |
| FY2023 | 3.9% | 9.6% | 62.7% |
| FY2022 | −15.1% | −11.2% | 56.1% |
| FY2021 | −19.7% | −18.4% | 53.5% |
| FY2020 | −10.8% | −7.7% | 58.2% |
| FY2019 | 3.0% | 7.9% | 69.4% |
| FY2018 | 7.7% | 17.5% | 63.8% |
| FY2017 | −0.6% | 16.0% | 55.3% |
| FY2016 | 3.1% | 15.6% | 62.1% |
| FY2015 | 20.1% | 42.8% | 83.4% |
| FY2014 | 51.4% | 35.7% | 79.5% |
| FY2013 | 1.0% | 3.0% | 66.8% |
| FY2012 | n/a | n/a | n/a |
| FY2011 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 11.1% | +12.4 pts | 15.4% | |
| Q1 FY26 | 10.0% | +13.1 pts | 13.4% | |
| Q4 FY25 | 8.9% | +11.9 pts | 12.6% | |
| Q3 FY25 | 4.9% | +6.2 pts | 8.7% | |
| Q2 FY25 | −1.4% | −6.4 pts | 2.0% | |
| Q1 FY25 | −3.1% | −10.0 pts | 1.0% | |
| Q4 FY24 | −3.0% | −6.9 pts | 0.1% | |
| Q3 FY24 | −1.3% | −4.3 pts | 2.1% | |
| Q2 FY24 | 5.0% | +6.3 pts | 9.3% | |
| Q1 FY24 | 6.9% | +14.2 pts | 11.1% | |
| Q4 FY23 | 3.9% | +19.0 pts | 9.6% | |
| Q3 FY23 | 3.0% | +26.9 pts | 9.4% |
Against its peers
Companies in Drug Manufacturers - General nearest ANI Pharmaceuticals' size, closest first, today.
| Company | Profit margin |
|---|---|
| ANIPANI Pharmaceuticals | 11.1% |
| PAHCPhibro Animal Health | 6.6% |
| ANABAnaptysbio | n/m |
| PCRXPacira BioSciences | 2.0% |
| HRMYHarmony Biosciences | 18.9% |
| PBHPrestige Consumer Healthcare | 15.6% |
| OMEROmeros | n/m |
| AMPHAmphastar Pharmaceuticals | 10.8% |
| NRIXNurix Therapeutics | 42.0% |
| ABUSArbutus Biopharma | 84.2% |
| OGNOrganon | 3.4% |
| Peer median | 13.2% |
Where ANI Pharmaceuticals ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on ANI Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.